Acute Kidney Injury, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus, Hypertension
Conditions
Brief summary
The Stockholm CREAtinine Measurements (SCREAM) project is a healthcare utilization cohort including, at present, all adult residents in Stockholm between 2006 and 2021. The region of Stockholm had a population of 2.3 million citizens in 2021and provides universal healthcare with a single unified health-system. Administrative databases with complete information on socidemographic data, healthcare use, diagnoses and therapeutic/surgical procedures, and vital status were enriched with performed laboratory tests, dispensed prescriptions at Swedish pharmacies and validated kidney replacement therapy endpoints. Registries were linked and de-identified by the Swedish National Board of Welfare and are considered to have no or minimal loss to follow-up. Because the study utilized de-identified data, it was deemed not to require informed consent and was approved by the regional ethical review boards and the Swedish National Board of Welfare. For detailed description of available data and linked registers please consult: https://pubmed.ncbi.nlm.nih.gov/35028991/
Detailed description
Please consult cohort description in: https://pubmed.ncbi.nlm.nih.gov/35028991/ https://pubmed.ncbi.nlm.nih.gov/26798472/
Interventions
DRUGInitiation of specific medications
multiple therapies studied within this database
PROCEDUREUndertaking of specific procedures
multiple procedures/surgeries studied within this database
DIAGNOSTIC_TESTAbnormalities in specific laboratory tests
multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database
Sponsors
Region Stockholm
Karolinska Institutet
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 110 Years
Inclusion criteria
For both cohorts: Be a resident of Stockholm during 2006-2021, of all ages For the primary cohort: To have undertaken at least one test of serum creatinine or albuminuria during 2006-2021. If this condition is met, we will then extract a broad range of laboratory tests For the secondary cohort: Anyone not undertaking a test of serum creatinine or albuminuria will conform the secondary cohort. In this cohort we will not extract any other laboratory test, but will obtain the rest of healthcare information
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse health events by levels of kidney function | 2006-2021 | multiple outcomes evaluated such as cardiovascular events, fractures, dementia, cancer, etc, all of them based on claims data and/or laboratory data |
| Safety and efficacy of medications by levels of kidney function | 2006-2021 | multiple outcomes evaluated depending on the treatments of interest, all of them based on claims data and/or laboratory data |
| Effect of medications or conditions on kidney function decline | 2006-2021 | Evaluation of changes in kidney function over time upon occurrence of a certain condition (i.e., heart failure or covid19 infection) or initiation of a specific medication |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse health events associated to laboratory abnormalities | 2006-2021 | Same as primary objectives but for other laboratory abnormalities different from kidney function measures |
Outcome results
None listed